CROSS COUNTRY HEALTHCARE INC (CCRN) Fundamental Analysis & Valuation
NASDAQ:CCRN • US2274831047
Current stock price
10.02 USD
-0.01 (-0.1%)
Last:
This CCRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CCRN Profitability Analysis
1.1 Basic Checks
- In the past year CCRN was profitable.
- In the past year CCRN had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: CCRN reported negative net income in multiple years.
- CCRN had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- CCRN has a worse Return On Assets (-21.13%) than 80.00% of its industry peers.
- CCRN's Return On Equity of -29.38% is on the low side compared to the rest of the industry. CCRN is outperformed by 68.00% of its industry peers.
- The Return On Invested Capital of CCRN (0.54%) is worse than 63.00% of its industry peers.
- CCRN had an Average Return On Invested Capital over the past 3 years of 6.06%. This is below the industry average of 8.51%.
- The 3 year average ROIC (6.06%) for CCRN is well above the current ROIC(0.54%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -29.38% | ||
| ROIC | 0.54% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
1.3 Margins
- The Operating Margin of CCRN (0.24%) is worse than 63.00% of its industry peers.
- In the last couple of years the Operating Margin of CCRN has declined.
- The Gross Margin of CCRN (20.26%) is comparable to the rest of the industry.
- CCRN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.24% | ||
| PM (TTM) | N/A | ||
| GM | 20.26% |
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
2. CCRN Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CCRN is destroying value.
- The number of shares outstanding for CCRN has been reduced compared to 1 year ago.
- CCRN has less shares outstanding than it did 5 years ago.
- CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 4.86 indicates that CCRN is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 4.86, CCRN belongs to the best of the industry, outperforming 87.00% of the companies in the same industry.
- There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.86 |
ROIC/WACC0.06
WACC8.9%
2.3 Liquidity
- CCRN has a Current Ratio of 3.78. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 3.78, CCRN belongs to the best of the industry, outperforming 87.00% of the companies in the same industry.
- A Quick Ratio of 3.78 indicates that CCRN has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.78, CCRN belongs to the top of the industry, outperforming 89.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.78 |
3. CCRN Growth Analysis
3.1 Past
- CCRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -95.56%.
- Measured over the past years, CCRN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.59% on average per year.
- Looking at the last year, CCRN shows a very negative growth in Revenue. The Revenue has decreased by -21.56% in the last year.
- CCRN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.74% yearly.
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
3.2 Future
- CCRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 175.50% yearly.
- CCRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.18% yearly.
EPS Next Y455.34%
EPS Next 2Y271.84%
EPS Next 3Y175.5%
EPS Next 5YN/A
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. CCRN Valuation Analysis
4.1 Price/Earnings Ratio
- CCRN is valuated quite expensively with a Price/Earnings ratio of 501.00.
- Compared to the rest of the industry, the Price/Earnings ratio of CCRN indicates a slightly more expensive valuation: CCRN is more expensive than 60.00% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.66. CCRN is valued rather expensively when compared to this.
- CCRN is valuated quite expensively with a Price/Forward Earnings ratio of 90.22.
- Based on the Price/Forward Earnings ratio, CCRN is valued a bit more expensive than the industry average as 60.00% of the companies are valued more cheaply.
- CCRN is valuated expensively when we compare the Price/Forward Earnings ratio to 38.00, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 501 | ||
| Fwd PE | 90.22 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CCRN is valued a bit cheaper than the industry average as 69.00% of the companies are valued more expensively.
- 86.00% of the companies in the same industry are more expensive than CCRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.05 | ||
| EV/EBITDA | 11.08 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- CCRN's earnings are expected to grow with 175.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.1
PEG (5Y)N/A
EPS Next 2Y271.84%
EPS Next 3Y175.5%
5. CCRN Dividend Analysis
5.1 Amount
- CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CCRN Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:CCRN (4/22/2026, 1:50:07 PM)
10.02
-0.01 (-0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-04 2026-03-04/amc
Earnings (Next)05-05 2026-05-05/amc
Inst Owners83.99%
Inst Owner Change-0.12%
Ins Owners7.09%
Ins Owner Change17.24%
Market Cap322.64M
Revenue(TTM)1.05B
Net Income(TTM)-94.85M
Analysts74.67
Price Target11.9 (18.76%)
Short Float %4.28%
Short Ratio2.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-157.94%
Min EPS beat(2)-296.08%
Max EPS beat(2)-19.79%
EPS beat(4)1
Avg EPS beat(4)-107.17%
Min EPS beat(4)-296.08%
Max EPS beat(4)5.59%
EPS beat(8)3
Avg EPS beat(8)-61.22%
EPS beat(12)6
Avg EPS beat(12)-39.22%
EPS beat(16)10
Avg EPS beat(16)-25.76%
Revenue beat(2)0
Avg Revenue beat(2)-9.09%
Min Revenue beat(2)-9.46%
Max Revenue beat(2)-8.72%
Revenue beat(4)0
Avg Revenue beat(4)-7.87%
Min Revenue beat(4)-9.46%
Max Revenue beat(4)-5.84%
Revenue beat(8)0
Avg Revenue beat(8)-4.22%
Revenue beat(12)2
Avg Revenue beat(12)-2.78%
Revenue beat(16)5
Avg Revenue beat(16)-1.59%
PT rev (1m)2.55%
PT rev (3m)1.87%
EPS NQ rev (1m)-4.59%
EPS NQ rev (3m)-388.87%
EPS NY rev (1m)13.77%
EPS NY rev (3m)-7.98%
Revenue NQ rev (1m)-0.3%
Revenue NQ rev (3m)-7.76%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-3.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 501 | ||
| Fwd PE | 90.22 | ||
| P/S | 0.31 | ||
| P/FCF | 8.05 | ||
| P/OCF | 6.69 | ||
| P/B | 1 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | 11.08 |
EPS(TTM)0.02
EY0.2%
EPS(NY)0.11
Fwd EY1.11%
FCF(TTM)1.25
FCFY12.43%
OCF(TTM)1.5
OCFY14.95%
SpS32.74
BVpS10.03
TBVpS7.19
PEG (NY)1.1
PEG (5Y)N/A
Graham Number2.12403 (-78.8%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -29.38% | ||
| ROCE | 0.68% | ||
| ROIC | 0.54% | ||
| ROICexc | 0.76% | ||
| ROICexgc | 1.17% | ||
| OM | 0.24% | ||
| PM (TTM) | N/A | ||
| GM | 20.26% | ||
| FCFM | 3.8% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
ROICexc(3y)6.35%
ROICexc(5y)14.73%
ROICexgc(3y)10.08%
ROICexgc(5y)21.91%
ROCE(3y)7.68%
ROCE(5y)18.37%
ROICexgc growth 3Y-70.95%
ROICexgc growth 5Y-31.89%
ROICexc growth 3Y-71.51%
ROICexc growth 5Y-28.12%
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
F-Score6
Asset Turnover2.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 48.59% | ||
| Cap/Sales | 0.77% | ||
| Interest Coverage | 1.82 | ||
| Cash Conversion | 249.59% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 4.86 |
F-Score6
WACC8.9%
ROIC/WACC0.06
Cap/Depr(3y)57.55%
Cap/Depr(5y)63.04%
Cap/Sales(3y)0.7%
Cap/Sales(5y)0.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
EPS Next Y455.34%
EPS Next 2Y271.84%
EPS Next 3Y175.5%
EPS Next 5YN/A
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5YN/A
EBIT growth 1Y103.69%
EBIT growth 3Y-79.18%
EBIT growth 5Y-28.09%
EBIT Next Year307.2%
EBIT Next 3Y80.75%
EBIT Next 5YN/A
FCF growth 1Y-64.01%
FCF growth 3Y-31.6%
FCF growth 5Y12.15%
OCF growth 1Y-59.83%
OCF growth 3Y-28.87%
OCF growth 5Y12.15%
CROSS COUNTRY HEALTHCARE INC / CCRN Fundamental Analysis FAQ
What is the ChartMill fundamental rating of CROSS COUNTRY HEALTHCARE INC (CCRN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to CCRN.
What is the valuation status for CCRN stock?
ChartMill assigns a valuation rating of 4 / 10 to CROSS COUNTRY HEALTHCARE INC (CCRN). This can be considered as Fairly Valued.
What is the profitability of CCRN stock?
CROSS COUNTRY HEALTHCARE INC (CCRN) has a profitability rating of 2 / 10.
What is the valuation of CROSS COUNTRY HEALTHCARE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CROSS COUNTRY HEALTHCARE INC (CCRN) is 501 and the Price/Book (PB) ratio is 1.
Can you provide the financial health for CCRN stock?
The financial health rating of CROSS COUNTRY HEALTHCARE INC (CCRN) is 9 / 10.